A Phase 2 interventional study of Vincristine and Dactinomycin in Rhabdomyosarcoma, sponsored by St. Jude Children's Research Hospital. Active, not recruiting at 4 sites in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital — 6 open to participants now, 9 under way, none of them phase 3. Rhabdomyosarcoma · St. Jude Children's Research Hospital.
Among the 17 studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 2, and was the 10th registered.
238 studies on the registry are indexed under Rhabdomyosarcoma; 49 are open to participants now.
Browse Rhabdomyosarcoma studies →6 of the 17 studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
St. Jude Children's Research Hospital · Sites in United States, Canada
Ages 12 mo–30 yrs
St. Jude Children's Research Hospital · Sites in United States
By country, each count listing its studies:
Of the 39 Rhabdomyosarcoma studies recruiting now, 8 (21%) set no upper age limit and 31 (79%) stop at 75 or younger; 35 take children under 18; none take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6
First in 2000; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is above the median of 42 across 202 interventional studies indexed under Rhabdomyosarcoma.
Median enrollment 94 across the 14 interventional studies, 1,000 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
4 of the studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01871766St. Jude Children's Research HospitalRisk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | 2026-12 |
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT04897321St. Jude Children's Research HospitalB7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | 2027-03-01 |
| NCT00840047St. Jude Children's Research HospitalMethionine PET/CT Studies In Patients With Cancer | 2027-07-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will treat participants with newly diagnosed, low, intermediate and high risk rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified dose chemotherapy, radiation and surgical resection. Intermediate and high risk participants will receive an additional 12 weeks (4 cycles) of maintenance therapy with anti-angiogenic chemotherapy.
PRIMARY OBJECTIVE:
SECONDARY OBJECTIVES:
Participants will be stratified based on both a pretreatment staging system and a post-surgery surgico/pathologic clinical grouping system. Treatment for low-risk (subset 1) participants will consist of chemotherapy and radiation. Low-risk (subset 2) and intermediate-risk participants will receive chemotherapy and radiation and/or undergo surgery to destroy/remove the tumor. Intermediate-risk participants will also receive 16 weeks of maintenance chemotherapy. High-risk participants will receive chemotherapy and radiation therapy. High-risk participants will also receive additional maintenance therapy with anti-angiogenic chemotherapy.
Inclusion Criteria:
Must have either low-, intermediate-, or high-risk disease, defined as:
Adequate bone marrow function defined as:
Adequate renal function defined as:
Exclusion Criteria:
Inclusion Criteria for Contrast-Enhanced Ultrasound (CEUS) Sub-Study:
Exclusion Criterial for CEUS Sub-Study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed. Participants also receive \^1\^1C-methionine as described in the intervention section.
Drug: Vincristine · Drug: Dactinomycin · Drug: Cyclophosphamide · Procedure: Surgical Resection · Procedure: Radiation · Drug: Myeloid Growth Factor · Procedure: Lymph Node Sampling · Drug: ^1^1C-methionine
Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed. Participants also receive \^1\^1C-methionine as described in the intervention section.
Drug: Vincristine · Drug: Dactinomycin · Drug: Cyclophosphamide · Procedure: Radiation · Drug: Myeloid Growth Factor · Procedure: Lymph Node Sampling · Drug: ^1^1C-methionine
Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed. Participants also receive \^1\^1C-methionine as described in the intervention section.
Drug: Vincristine · Drug: Dactinomycin · Drug: Cyclophosphamide · Procedure: Surgical Resection · Procedure: Radiation · Drug: Bevacizumab · Drug: Sorafenib · Drug: Myeloid Growth Factor · Procedure: Lymph Node Sampling · Drug: ^1^1C-methionine
Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy \[vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)\] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed. Participants also receive \^1\^1C-methionine as described in the intervention section.
Drug: Vincristine · Drug: Dactinomycin · Drug: Cyclophosphamide · Procedure: Surgical Resection · Procedure: Radiation · Drug: Bevacizumab · Drug: Sorafenib · Drug: Myeloid Growth Factor · Procedure: Lymph Node Sampling · Drug: Irinotecan · Drug: Ifosfamide · Drug: Etoposide · Drug: Etoposide Phosphate · Drug: Doxorubicin · Drug: Dexrazoxane · Drug: ^1^1C-methionine
Dosage and route of administration: * \< 1 year of age=0.025 mg/kg intravenously (IV) * \> 1 year and \< 3 years= 0.05 mg/kg IV * ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants.
Also known as: Oncovin®
Dosage and route of administration: * \< 1 year=0.025 mg/kg IV push * ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
Also known as: Actinomycin-D, Cosmegen®
Dosage and route of administration: During VAC chemotherapy: * \< 3 years of age = 40 mg/kg IV * ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA. During maintenance for intermediate-risk participants: * oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)
Also known as: Cytoxan(R)
Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
Also known as: Surgery
Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
Also known as: Proton Beam Radiation, External Beam Radiation, Brachytherapy
Dosage and route of administration: 15 mg/kg/dose/day IV.
Also known as: rhuMab, VEGF, Avastin®
Dosage and route of administration: 90 mg/m\^2/dose twice daily.
Also known as: Nexavar®
If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice. High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.
Also known as: G-CSF, Filgrastim, Pegfilgrastim
Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in "at risk" patients.
Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.
Also known as: Camptosar ®
Dosage and Route of Administration: During interval compressed therapy - Age \> 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.
Also known as: Ifex ®
Dosage and Route of Administration: Age \>1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis
Also known as: VP-16, Vepesid®
Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.
Also known as: Etopophos®
Dosage and route of Administration: Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.
Also known as: Adriamycin®
Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin. Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes.
Also known as: Zinecard
Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Also known as: Contrast Media
Event-free survival (intermediate risk arm)
To estimate event-free survival for intermediate risk participants treated by vincristine-dactinomycin-cyclophosphamide (VAC) with the addition of maintenance anti-angiogenic therapy
Time frame: 2 years after last intermediate risk arm enrollment
Event-free survival (high risk arm)
To estimate event-free survival for high risk participants.
Time frame: 5 years after last high-risk arm enrollment
Rate of false negative and false positive the sentinel lymph node procedure (low and intermediate risk arms)
Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.
Time frame: 2 years after last low or intermediate arm enrollment
Rate of false negative and false positive the sentinel lymph node procedure (high risk arm)
Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.
Time frame: 5 years after last high risk arm enrollment
Local failure rate (low and intermediate risk arms)
Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation
Time frame: 2 years after last low or intermediate risk arm enrollment
Local failure rate (high risk arm)
Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation
Time frame: 5 years after last high risk arm enrollment
Patterns of failure (low and intermediate risk arms)
Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume
Time frame: 2 years after last low or intermediate risk arm enrollment
Patterns of failure (high risk arm)
Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume
Time frame: 5 years after last high risk arm enrollment
Number of patients that complete all cycles of maintenance chemotherapy (intermediate risk arm)
Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in intermediate risk patients following standard chemotherapy.
Time frame: 2 years after last low or intermediate risk arm enrollment
Number of patients that complete all cycles of maintenance chemotherapy (high risk arm)
Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in high risk patients following standard chemotherapy.
Time frame: 5 years after last high risk arm enrollment
Incidence of CTC grade 3 and higher toxicities related to proton bream therapy (low and intermediate and high risk arms)
Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy.
Time frame: 2 years after last enrollment
Started Dec 2013 (actual). Primary completion is estimated for Dec 2026, 156 months after the start.
Of 36 non-industry phase 2 interventional studies under Rhabdomyosarcoma, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 156 months is above that.
Counting every sponsor, half of 39 studies reached it within 63 months; a quarter within 40 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Sorafenib · Irinotecan · Ifosfamide · Etoposide · Etoposide phosphate · Doxorubicin · Dexrazoxane
St. Jude Children's Research Hospital →